Navigation Links
Researchers find no difference in drugs for macular degeneration
Date:9/30/2010

(Boston) Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). The study, which appears currently on-line in Eye, is believed to be the first study to describe one-year outcomes of a prospective, double-masked, randomized clinical trial directly comparing bevacizumab to ranibizuamab. Last October, these same researchers published early, six month outcomes of the same study, which also failed to show a difference in efficacy between these two drugs for treating AMD.

AMD is the leading cause of blindness over the age of 50 in developed Western countries. It presents in two forms, exudative (wet) or nonexudative (dry). Wet AMD is often more visually devastating with a higher risk of blindness. The gold standard of treatment for wet AMD is ranibizumab (Lucentis, Genentech Inc.), which was FDA approved as an eye injection in 2006. Bevacizumab (Avastin, Genentech Inc.) was FDA approved for the treatment of colorectal cancer in 2004, but has also been used worldwide in an off-label fashion as an eye injection for the treatment of wet AMD. Lucenitis costs approximately $2000.00 per injection, while Avastin costs approximately $50.00 per injection. While both drugs have shown independently to be effective in treating wet AMD, it was uncertain if both drugs were equally efficacious or if either one was better.

In this study, patients were enrolled by a 2:1 ratio to receive either the Avastin or Lucentis. Patients were given eye injections of Avastin or Lucentis every month for the first three months, followed by monthly examination and testing. They received further injections on an as needed basis for one year.

Fifteen patients received Avastin and seven patients received Lucentis. There was no significa
'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Researchers advance biosynthesis of potent anti-cancer drug Taxol
2. Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol
3. Researchers at the University of Granada associate trigger points with shoulder injury
4. Researchers to study effects of Mass. health reform
5. IU researchers: Chemotherapy alters brain tissue in breast cancer patients
6. Researchers use CT to predict heart disease
7. VCU study: Researchers discover a drug combination that shrinks tumors in vivo
8. Sugary sports drinks mistakenly associated with being healthy, say UTHealth researchers
9. Researchers create first molecule blocks key component of cancer genes on-off switch
10. Researchers create first molecule-blocks key component of cancer genes on-off switch
11. Team of researchers finds possible new genetic risk for Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... Calif., April 17, 2014 By discovering a new ... after a stroke, researchers at UC Irvine and the ... that may limit or prevent stroke-induced brain damage. , ... fourth-leading cause of death and primary reason for disability ... in a stroke and lets blood-borne material into the ...
(Date:4/17/2014)... 17, 2014 EcoHealth Alliance, a nonprofit organization that ... a comprehensive review today examining the current state of ... review calls for improved global surveillance strategies to combat ... outbreak of Ebola in West Africa that has claimed ... Guinea and Liberia. According to the World Health ...
(Date:4/17/2014)... online has the potential to ward off depression among ... research published online in The Journals of ... . In the article " Internet Use and Depression ... Longitudinal Analysis ," the authors report that Internet use ... percent among their study sample. , Late-life depression ...
(Date:4/17/2014)... April 2014) Population Council scientists and their partners have ... and can prevent the transmission of multiple sexually transmitted ... animals: HIV, herpes simplex virus 2 (HSV-2), and human ... data that the gel is effective against multiple strains ... the vagina against all three viruses of at least ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
Breaking Medicine News(10 mins):Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... 25, 2007) George Mason University professor of ... grant from the National Institutes of Health to ... Alzheimer,s disease. His program, "Apolipoprotein, Attention and Alzheimer,s ... and older adults for four years using cognitive, ...
... The Partnership to,Fight Chronic Disease (PFCD) announced today ... all 2008 presidential candidates to address the,country,s chronic disease ... reform will be the most important domestic issue in ... and,Professor and Chair of the Rollins School of Public ...
... National Marrow Donor Program,s Office of Patient Advocacy receives ... to help cancer survivors like Ryan, MINNEAPOLIS, Sept. 25 ... most of his life. Diagnosed with acute,myelogenous leukemia at just ... marrow or cord blood transplant to survive. Ryan received ...
... the, importance of staying active and eating healthy ... Calif., Sept. 25 Blue Cross of,California, collaborating ... Sports, is launching a 14-week statewide mobile,outreach campaign ... to make,healthy lifestyle choices now and in the ...
... Natural Cottage Cheese and NBC 10 Seek the Next Local ... in This Year,s Healthy Lifestyle ... massage,therapist, a 35-year-old administrative assistant, a 41-year-old comedian,and computer help ... teacher have in common? They,re all contestants in,"The Friendship All ...
... results from the randomized, double -blind,placebo -controlled, Phase ... of ZD4054 - a,specific endothelin A (ETA) receptor ... European,Congress of Clinical Oncology (ECCO, 23-27 September, Barcelona). ... in development for the treatment of men with ...
Cached Medicine News:Health News:George Mason University professor receives $2.6 million NIH grant to study Alzheimer's disease 2Health News:Partnership to Fight Chronic Disease Announces 'Ideas for Change' in Health Care 2Health News:Partnership to Fight Chronic Disease Announces 'Ideas for Change' in Health Care 3Health News:Young Twin Cities Boy Shows There is Life After Cancer 2Health News:Blue Cross of California and the California Governor's Council on Physical Fitness and Sports Launch 'Live Like a Champion Tour' 2Health News:Blue Cross of California and the California Governor's Council on Physical Fitness and Sports Launch 'Live Like a Champion Tour' 3Health News:Five Local Residents Vie to be Philadelphia's Biggest 2007 'Local Loser' 2Health News:Five Local Residents Vie to be Philadelphia's Biggest 2007 'Local Loser' 3Health News:Five Local Residents Vie to be Philadelphia's Biggest 2007 'Local Loser' 4Health News:Survival data presented from phase II study of hormone-resistant prostate cancer patients 2
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis ... results from two pre-clinical studies that,support the ... rich in,cysteine) expression in cancer and Abraxis' ... Association for Cancer Research (AACR) Annual Meeting ...
... Transurethral Resection,is Well Tolerated in Phase 2b Bladder ... --,Spectrum Pharmaceuticals, Inc., today announced results of a ... and the,presentation of preclinical data of SPI (IRL)-1620 ... Association of Cancer,Research, held at the Los Angeles ...
Cached Medicine Technology:Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 2Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 3Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 4Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 5Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 2Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 3Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 4Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 5Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 6Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 7Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 8
... known as bone Gla protein, is a ... a major component of the noncollagenous bone ... in bone, with a small amount produced ... [1]. During bone formation, newly synthesized osteocalcin ...
... Binding Protein-1 (IGFBP-1) is a phosphoprotein, produced ... and modulates the bioactivity of IGF-I and ... not been completely defined, but the nature ... be involved in glucose regulation and IGF-mediated ...
... factor binding protein 4 (IGFBP-4) is a 24 ... actions of IGF-I and IGF-II. It is also ... weight of 28 kDa. IGFBP-4 has been identified ... numerous cell types, including fibroblasts, neuroblastoma, prostate and ...
... Androstenedione, produced in the adrenal gland and ... testosterone and estrone, both of which may ... relatively weak androgenic activity, estimated at ~(less ... [1]. However, serum androstenedione levels often exceed ...
Medicine Products: